Pharma groups unimpressed by EU position on antimicrobial R&D

Incentives for treatment development must be predictable and backed with money, says Efpia

Drug company representatives have criticised EU recommendations to incentivise the development of new treatments for disease-causing microorganisms that have evolved to withstand existing medicines, a phenomenon called antimicrobial resistance.

On 13 June, the Council of the EU member state governments adopted a recommendation to advance the bloc’s actions to combat AMR, which is estimated to kill more than 1m people per year globally and is expected to worsen unless more action is taken.